A Repertoire of Novel Antibacterial Diastereomeric Peptides with Selective Cytolytic Activity*

(Received for publication, February 7, 1997, and in revised form, April 2, 1997)

Ziv Oren , Jiang Hong and Yechiel Shai Dagger

From the Department of Membrane Research and Biophysics, Weizmann Institute of Science, Rehovot 76100, Israel

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES


ABSTRACT

The increase in infectious diseases and bacterial resistance to antibiotics has resulted in intensive studies focusing on the use of linear, alpha -helical, cytolytic peptides from insects and mammals as potential drugs for new target sites in bacteria. Recent studies with diastereomers of the highly potent cytolytic peptides, pardaxin and melittin, indicate that alpha -helical structure is required for mammalian cells lysis but is not necessary for antibacterial activity. Thus, hydrophobicity and net positive charge of the polypeptide might confer selective antibacterial lytic activity. To test this hypothesis, a series of diastereomeric model peptides (12 amino acids long) composed of varying ratios of leucine and lysine were synthesized, and their structure and biological function were investigated. Peptide length and the position of D-amino acids were such that short peptides with stretches of only 1-3 consecutive L-amino acids that cannot form an alpha -helical structure were constructed. Circular dichroism spectroscopy showed that the peptides do not retain any detectable secondary structure in a hydrophobic environment. This enabled examination of the sole effect of hydrophobicity and positive charge on activity. The data reveal that modulating hydrophobicity and positive charge is sufficient to confer antibacterial activity and cell selectivity. A highly hydrophobic diastereomer that permeated both zwitterionic and negatively charged phospholipid vesicles, lysed eukaryotic and prokaryotic cells. In contrast, a highly positively charged diastereomer that only permeated slightly negatively charged phospholipid vesicles had low antibacterial activity and could not lyse eukaryotic cells. In the boundary between high hydrophobicity and high positive charge, the diastereomers acquired selective and potent antibacterial activity. Furthermore, they were completely resistant to human serum inactivation, which dramatically reduces the activity of native antibacterial peptides. In addition, a strong synergistic effect was observed at nonlethal concentrations of the peptides with the antibiotic tetracycline on resistant bacteria. The results are discussed in terms of proposed mechanisms of antibacterial activity, as well as a new strategy for the design of a repertoire of short, simple, and easily manipulated antibacterial peptides as potential drugs in the treatment of infectious diseases.


INTRODUCTION

Infectious diseases are increasing phenomena today mainly as a result of changes in the spectrum of pathogens and the increase in antibiotic-resistant pathogens. When antibiotics were first introduced, the proportion of resistant versus nonresistant pathogens was less than 1%, but this percentage has dramatically increased within 12 years of their uses. Although the number of antibacterial products available today is impressive (about 150), they cover only six different target sites and are dominated by beta -lactams, tetracyclines, aminoglycosides, marcolides, sulfonamides, and quinolones (1). The search for new target sites has resulted in an increased interest in antibacterial peptides that could serve as potential therapeutic drugs. Antibacterial peptides were initially discovered in invertebrates (2, 3) and subsequently in vertebrates, including humans (4). Antibacterial peptides serve as a defense system in addition or complementary to the highly specific cell-mediated immune response. This secondary, chemical immune system provides organisms with a repertoire of small peptides that are synthesized promptly upon induction and that act against invasion by occasional and obligate pathogens as well as against the uncontrolled proliferation of commensal microorganisms (5-7). So far, more than 100 different antibacterial peptides have been isolated and characterized. Most of them appear to act by direct lysis of the pathogenic cell membrane. A major group within this family are short linear polypeptides (<= 40 amino acids), which are devoid of disulfide bridges (6). These polypeptides vary considerably in chain length, hydrophobicity, and overall charge distribution but share a common structure upon association with lipid bilayers, namely, an amphipathic alpha -helical structure (8). Unlike bee venom melittin (9) and the neurotoxin pardaxin (10, 11) that are cytotoxic to both bacteria and mammalian cells (12, 13), antibacterial peptides are active only against bacteria. These peptides include the cecropins isolated from the cecropia moth (2), the magainins (3), and dermaseptins (14) isolated from frogs skin.

Numerous studies conducted on various native antibacterial peptides tend to emphasize the importance of an amphipathic alpha -helical structure and a net positive charge for cytolytic activity. The positive charge facilitates peptides interaction with the negatively charged membranes (15-18) found in higher concentrations in the pathogenic cell membrane as compared with normal eukaryotic cells, and the amphipathic alpha -helical structure is essential for lytic activity (18, 19). Studies using model antibacterial peptides focused on chain length and amino acid composition, as well as amphipathic structure (20-24). Most of these studies simultaneously examined at least three parameters, making it difficult to distinguish between the effect of each individual parameter on the overall biological activity. Nevertheless, these studies proved that an amphipathic alpha -helix and a net positive charge are required for antibacterial activity.

In previous studies, D-amino acids were incorporated into the cytolytic peptides pardaxin (25) and melittin (26). The resulting diastereomers did not retain their alpha -helical structure, which caused abrogation of their cytotoxic effects on mammalian cells. However, the diastereomers retained high antibacterial activity. These results suggest that hydrophobicity and a net positive charge confer selective antibacterial activity to nonselective cytolytic peptides and that amphipathic alpha -helical structure is not required. However, the diastereomers of pardaxin and melittin contained long stretchs of L-amino acids (14-17 amino acids long), which raises the possibility that the low residual helicity could be sufficient for membrane binding and destabilization.

To examine whether modulating hydrophobicity and the net positive charge of linear cytotoxic polypeptides is sufficient to confer selective antibacterial activity, we chose to investigate diastereomers of short model peptides (12 amino acids long), composed of varying ratios of leucine and lysine and one third of their sequence composed of D-amino acids. Peptide length and the position of D-amino acids were such that short peptides with very short consecutive stretches of 1-3 L-amino acids that cannot form an alpha -helical structure were constructed. The diastereomers were evaluated with regard to 1) their cytotoxicity against bacteria and human erythrocytes, 2) their structure, and (3) their ability to interact and perturb the morphology of the bacterial wall and model phospholipid membranes. The data show that modulating hydrophobicity and positive charge is sufficient to confer antibacterial activity and cytolytic selectivity. Furthermore, the resulting antibacterial peptides act synergistically at nonlethal concentrations with antibacterial drugs such as tetracycline, and they are totally resistant to human serum inactivation that dramatically reduces the activity of native antibacterial peptides. The results are discussed in light of proposed mechanisms of antibacterial activity, as well as a new strategy for the design of a repertoire of short, simple, and easily manipulated antibacterial peptides as potential drugs in the treatment of infectious diseases.


EXPERIMENTAL PROCEDURES

Materials

Butyloxycarbonyl-(amino acid)-(phenylacetamido)methylresin was purchased from Applied Biosystems (Foster City, CA), and butyloxycarbonyl amino acids were obtained from Peninsula Laboratories (Belmont, CA). Other reagents used for peptide synthesis included trifluoroacetic acid (Sigma), N,N-diisopropylethylamine (Aldrich, distilled over ninhydrin), dicyclohexylcarbodiimide (Fluka), 1-hydroxybenzotriazole (Pierce), and dimethylformamide (peptide synthesis grade, Biolab). Egg phosphatidylcholine (PC)1 was purchased from Lipid Products (South Nutfield, UK). Egg phosphatidylglycerol (PG) and phosphatidylethanolamine (PE) (Type V, from Escherichia coli) were purchased from Sigma. Cholesterol (extra pure) was supplied by Merck (Darmstadt, Germany) and recrystallized twice from ethanol. 3,3'-diethylthio-dicarbocyanine iodide (diS-C2-5) was obtained from Molecular Probes (Eugene, OR). All other reagents were of analytical grade. Buffers were prepared in double glass-distilled water.

Peptide Synthesis and Purification

Peptides were synthesized by a solid phase method on butyloxycarbonyl-(amino acid)-(phenylacetamido) methyl resin (0.05 meq) (27). The resin-bound peptides were cleaved from the resins by hydrogen fluoride and after hydrogen fluoride evaporation extracted with dry ether. These crude peptide preparations contained one major peak, as revealed by reversed phase HPLC, that was 50-70% pure peptide by weight. The synthesized peptides were further purified by reversed phase HPLC on a C18 reversed phase Bio-Rad semi-preparative column (250 × 10 mm, 300 Å pore size, 5 µM particle size). The column was eluted in 40 min, using a linear gradient of 5-60% acetonitrile in water, both containing 0.05% trifluoroacetic acid (v/v), at a flow rate of 1.8 ml/min. The purified peptides, which were shown to be homogeneous (>95%) by analytical HPLC, were subjected to amino acid analysis and mass spectroscopy to confirm their composition.

Transamidation of the Peptides

Resin-bound peptide (20 mg) was treated for 3 days with a mixture composed of saturated ammonia solution (30%) in methanol and Me2SO (1:1 v/v), which resulted in transamidation of the carboxylate group of the lysine residue located at the C terminus of all analogues. Thus, peptides were obtained in which all the protecting groups remained attached, but whose C-terminal residues were modified by one amide group. The methanol and ammonia were evaporated under a stream of nitrogen, and the Me2SO was evaporated by lyophilization. The resulting protected peptides were then extracted from the resin with fresh Me2SO and precipitated with dry ether. The products were subjected to hydrogen fluoride cleavage and further purified by reversed phase HPLC as described above.

Preparation of Liposomes

Small unilamellar vesicles were prepared by sonication of PC/cholesterol (10:1 w/w) or PE/PG (7:3 w/w) dispersions. Dry lipid mixtures were dissolved in a CHCl3/MeOH mixture (2:1 v/v). The solvents were then evaporated under a stream of nitrogen, and the lipids (at a concentration of 7.2 mg/ml) were subjected to a vacuum for 1 h and then resuspended in the appropriate buffer by vortexing. The resulting lipid dispersions were then sonicated for 5-15 min in a bath type sonicator (Bransonic B3-R sonicator, Branson Ultrasonics Corporation, Danbury, CT) until clear. The lipid concentrations of the resulting preparations were determined by phosphorus analysis (28). Vesicles were visualized using a JEOL JEM 100B electron microscope (Japan Electron Optics Laboratory Co., Tokyo, Japan) as follows: A drop of vesicles was deposited on a carbon-coated grid and negatively stained with uranyl acetate. Examination of the grids demonstrated that the vesicles were unilamellar, with an average diameter of 20-50 nm (29).

Preparation of Serum

Blood was collected from five volunteers and allowed to clot at room temperature for 4 h. The blood was then centrifuged for 15 min at 1500 × g, and the serum was removed and pooled. The serum complement was inactivated by heating at 56 °C for 30 min.

CD Spectroscopy

The CD spectra of the peptides were measured with a Jasco J-500A spectropolarimeter. The spectra were scanned at 23 °C in a capped, quartz optical cell with a 0.5-mm path length. Spectra were obtained at wavelengths of 250-190 nm. Eight scans were taken for each peptide at a scan rate of 20 nm/min. The peptides were scanned at concentrations of 1.5 × 10-5-2.0 × 10-5 M in 40% trifluoroethanol. Fractional helicities (30, 31) were calculated as follows:
f<SUB>h</SUB>=<FR><NU>[&thgr;]<SUB>222</SUB>−[&thgr;]<SUP>0</SUP><SUB>222</SUB></NU><DE>[&thgr;]<SUP>100</SUP><SUB>222</SUB>−[&thgr;]<SUP>0</SUP><SUB>222</SUB></DE></FR> (Eq. 1)
where theta 222 is the experimentally observed absolute mean residue ellipticity at 222 nm, and values for theta 2220 and theta 222100, corresponding to 0 and 100% helix content at 222 nm, estimated at 2,000 and 32,000 degrees·cm2/dmol, respectively.

Antibacterial Activity of Diastereomeric Model Peptides

The antibacterial activity of the diastereomers was examined in sterile 96-well plates (Nunc F96 microtiter plates) in a final volume of 100 µl as follows. Aliquots (50 µl) of a suspension containing bacteria at a concentration of 106 colony-forming units/ml LB medium were added to 50 µl of water or 66% pooled normal human serum in PBS, containing the peptide in 2-fold serial dilutions. Growth inhibition was determined by measuring the absorbance at 492 nm with a Microplate autoreader El309 (Bio-tek Instruments), following incubation for 18-20 h at 37 °C. Antibacterial activity is expressed as the minimal inhibitory concentration (MIC), the concentration at which 100% inhibition of growth was observed after 18-20 h of incubation. The bacteria used were: E. coli D21, Acinetobacter calcoaceticus Ac11, Pseudomonas aeruginosa ATCC 27853, Bacillus megaterium Bm11, and Bacillus subtilis ATCC 6051.

Synergistic Effect between Tetracycline and the Diastereomers

To investigate a possible synergistic relationship between the antibiotic drug tetracycline and the diastereomers, tetracycline was tested in 2-fold serial dilutions against P. aeruginosa (ATCC 27853) in the presence of a constant equimolar concentration (1 µM) of [D]-L3,4,8,10-K5L7. Antibacterial activity of the mixtures was determined as described above.

Hemolysis of Human Red Blood Cells

Hemolytic activity of the peptides were tested against human red blood cells (hRBC). Fresh hRBC with EDTA were rinsed three times with PBS (35 mM phosphate buffer/0.15 M NaCl, pH 7.3) by centrifugation for 10 min at 800 × g and resuspended in PBS. Peptides dissolved in PBS were then added to 50 µl of a solution of the stock hRBC in PBS to reach a final volume of 100 µl (final erythrocyte concentration, 5% v/v). The resulting suspension was incubated under agitation for 30 min at 37 °C. The samples were then centrifuged at 800 × g for 10 min. Release of hemoglobin was monitored by measuring the absorbance of the supernatant at 540 nm. Controls for zero hemolysis (blank) and 100% hemolysis consisted of hRBC suspended in PBS and Triton 1%, respectively.

Peptides Induced Membrane Permeation

Membrane permeation was assessed utilizing the diffusion potential assay (32, 33) as described previously (34, 35). In a typical experiment, in a glass tube, 4 µl of a liposome suspension (final phospholipid concentration, 32 µM) in a K+ containing buffer (50 mM K2SO4, 25 mM HEPES-SO4-2, pH 6.8), was diluted in 1 ml of an isotonic K+ free buffer (50 mM Na2SO4, 25 mM HEPES-SO4-2, pH 6.8), and the fluorescent, potential-sensitive dye diS-C2-5 was then added. Valinomycin (1 µl, 10-7 M) was added to the suspension to slowly create a negative diffusion potential inside the vesicles, which led to a quenching of the dye's fluorescence. Once the fluorescence had stabilized, which took 3-10 min, peptides were added. The subsequent dissipation of the diffusion potential, as reflected by an increase in fluorescence, was monitored on a Perkin-Elmer LS-50B spectrofluorometer, with the excitation set at 620 nm, the emission set at 670 nm, and the gain adjusted to 100%. The percentage of fluorescence recovery, Ft, was defined as:
F<SUB><UP>t</UP></SUB>=(I<SUB><UP>t</UP></SUB>−I<SUB>0</SUB>/I<SUB><UP>f</UP></SUB>−I<SUB>0</SUB>)×100 (Eq. 2)
where I0 represents the initial fluorescence, If represents the total fluorescence observed before the addition of valinomycin, and It represents the fluorescence observed after adding the peptide at time t.

Visualization of the Effect of the Peptides on Bacteria Using Electron Microscopy

Samples containing E. coli (106 colony-forming units/ml) in LB medium were incubated with the various peptides at their MIC and 80% of the MIC for 1 h and then centrifuged for 10 min at 3000 × g. The pellets were resuspended, and a drop containing the bacteria was deposited onto a carbon-coated grid, which was then negatively stained with 2% phosphotungstic acid, pH 6.8. The grids were examined using a JEOL JEM 100B electron microscope.


RESULTS

Diastereomers Design

Four diastereomers of linear and short (12 amino acids long) model peptides composed of varying ratios of lysine-to-leucine were synthesized in order 1) to examine whether a balance between hydrophobicity and a net positive charge may be a sufficient criteria necessary for selective bacterial lysis and 2) to gain insight into the mechanism underlying this effect. The location of D-amino acids remained constant in all peptides, because it was constructed for maximum disruption of alpha -helical structure. D-Amino acids were distributed along the peptide, leaving only very short stretches of 1-3 consecutive L-amino acids. The peptides were then characterized with regard to their structure, biological function, and interaction with bacteria and model membranes composed of either zwitterionic or negatively charged phospholipids. The following peptides were synthesized; [D]-L3,4,8,10-K3L9, [D]-L3,4,8,10-K4L8, [D]-L3,4,8,10-K5L7, and [D]-L3,4,8,10-K7L5 (Table I). The hydrophobicities (36) and net positive charge of the peptides are listed in Table I.

Table I. Sequences, designations, hydrophobicity, and net charge of the peptides investigated


Peptide designation Sequencea Net charge Hydrophobicityb

[D]-L3,4,8,10-K3L9 K L L L L L K L K-NH2 +4 0.12
[D]-L3,4,8,10-K4L8 K L L L K L L L K-NH2 +5  -0.01
[D]-L3,4,8,10-K5L7 K L L L K L K L K-NH2 +6  -0.15
[D]-L3,4,8,10-K7L5 K K L L K L K K K-NH2 +8  -0.42

a Underlined and bold amino acids are D-enantiomers. The C terminus is amidated.
b Mean values of hydrophobicity were calculated using consensus value of hydrophobicity scale (36).

CD Spectroscopy

The extent of the alpha -helical structure of the diastereomers was determined from their CD spectra in 40% trifluoroethanol, a solvent that strongly promotes alpha -helical structure. As expected, after incorporation of D-amino acids, no signal was observed for all the diastereomers, demonstrating the lack of any specific secondary structure (data not shown). In a recent study, a peptide with a sequence identical to that of [D]-L3,4,8,10-K4L8 but composed of only L-amino acids was found to have ~40% alpha -helical structure in methanol and in L-alpha -dimyristoylphosphatidylcholine vesicles (22).

Antibacterial and Hemolytic Activity of the Peptides

The hemolytic activity of the peptides against the highly cytolytically susceptible human erythrocytes was tested. A dose-response curve for the hemolytic activity of the peptides is shown in Fig. 1. The hemolytic activity of bee venom melittin served as a control. A direct correlation was found between the hydrophobicity (Table I) and the hemolytic activity of the diastereomers. [D]-L3,4,8,10-K3L9, which has the highest hydrophobicity, was the most hemolytic peptide. However, its hemolytic activity is very low in comparison with that of melittin (>60-fold less activity). All the other peptides showed no significant hemolytic activity up to the maximum concentration tested (100 µm) (Fig. 1). It should be noted that although [D]-L3,4,8,10-K4L8 is not hemolytic at concentrations >100-fold of those required for significant hemolysis by melittin, its entirely L-amino acid form, [D]-L3,4,8,10-K4L8, has hemolytic activity close to that of melittin (~5-fold less) (22).


Fig. 1. Dose-response curve of the hemolytic activity of the peptides toward hRBC. The assay was performed as described under "Experimental Procedures." The inset shows the assay results at low concentration. Designations are as follows: square , melittin; black-square, [D]-L3,4,8,10-K3L9; bullet , [D]-L3,4,8,10-K4L8; black-triangle, [D]-L3,4,8,10-K5L7. The activity of [D]-L3,4,8,10-K7L5 is identical to that of [D]-L3,4,8,10-K5L7 and therefore not shown.
[View Larger Version of this Image (19K GIF file)]

The peptides were also tested for their antibacterial activity against a representative set of bacteria, including three Gram-negative species (E. coli, A. calcoaceticus, and P. aeruginosa) and two Gram-positive species (B. megaterium and B. subtilis). The antibiotic tetracycline, the native antibacterial peptide dermaseptin S, and the cytolytic peptide melittin served as controls. The resultant MICs are shown in Table II. The data show that the antibacterial activity of the diastereomers was modulated by the balance between hydrophobicity and positively charged amino acids. Both the most hydrophobic peptide, [D]-L3,4,8,10-K3L9, and the most hydrophilic peptide, [D]-L3,4,8,10-K7L5, displayed the lowest range in antibacterial activity (Table II). However, [D]-L3,4,8,10-K4L8 and [D]-L3,4,8,10-K5L7 displayed high antibacterial activity against most of the bacteria tested with the former being slightly more potent. Furthermore, each peptide had a unique spectrum of antibacterial activity, and each was active more against Gram-positive as compared with Gram-negative bacteria.

Table II. Minimal inhibitory concentration of the peptides


Peptide designation Minimal inhibitory concentrationa
E. coli (D21) A. calcoaceticus (Ac11) P. aeruginosa (ATCC-27853) B. megaterium (Bm11) B. subtilis (ATCC-6051)

µM
[D]-L3,4,8,10-K3L9 9 20 125 0.7 1.1
[D]-L3,4,8,10-K4L8 3.5 4 10 0.4 0.5
[D]-L3,4,8,10-K5L7 7 20 10 0.25 2
[D]-L3,4,8,10-K7L5 80 200 >200 1 100
Dermaseptin S 6 3 25 0.5 4
Melittin 5 2 25 0.3 0.6
Tetracycline 1.5 1.5 50 1.2 6.5

a Results are the mean of three independent experiments, each performed in duplicates with a standard deviation of 20%.

Synergistic Effects and Antibacterial Activity of the Diastereomers in Serum

We observed a synergistic effect between the antibiotic drug tetracycline and the diastereomer [D]-L3,4,8,10-K5L7. Tetracycline shows little activity against P. aeruginosa. However, when mixed with 1 µM solution of [D]-L3,4,8,10-K5L7, a concentration that is 10-fold lower than that required for lytic activity against P. aeruginosa, an 8-fold increase in the activity of tetracycline was observed (Table III). A possible explanation for the synergistic effect is that the peptide slightly disrupts the bacterial wall, which improves partitioning of tetracycline into the bacteria. This is supported by electron microscopy studies showing that below its MIC [D]-L3,4,8,10-K5L7 causes morphological changes in the bacterial wall (see Fig. 3). In addition, the effect of pooled human serum on the antibacterial activity of [D]-L3,4,8,10-K5L7 and the native antibacterial peptide dermaseptin against P. aeruginosa and E. coli was found to differ considerably (Table III). Although dermaseptin was 8-10-fold less active in the presence of serum, [D]-L3,4,8,10-K5L7 retained its antibacterial activity.

Table III. Minimal inhibitory concentration in the presence of human serum and synergistic activity of [D]-L3,4,8,10-K5L7


Peptide designation Minimal inhibitory concentrationa
P. aeruginosa (ATCC-27853)
E. coli (D21)
0% serum 33% serum 0% serum 33% serum

[D]-L3,4,8,10-K5L7 10 10 7 7
Dermaseptin S 25 200 6 50
Tetracycline 50
Tetracycline + [D]-L3,4,8,10-K5L7 (1 µM) 6

a Results are the mean of two independent experiments, each performed in duplicates, with a standard deviation of 20%.


Fig. 3. Electron micrographs of negatively stained E. coli untreated and treated with the various peptides at 80% of their MIC. A and F, control bacteria. B, treated with [D]L3,4,8,10-K3L9. C and G, treated with [D]-L3,4,8,10-K4L8. D and H, treated with [D]-L3,4,8,10-K5L7. E, treated with [D]-L3,4,8,10-K7L5.
[View Larger Version of this Image (123K GIF file)]

Peptide-induced Membrane Permeation

Various concentrations of peptides were mixed with vesicles that had been pretreated with the fluorescent dye, diS-C2-5, and valinomycin. The kinetics of the fluorescence recovery was monitored, and the maximum fluorescence level was determined as a function of peptide concentration (Fig. 2). PC/cholesterol vesicles (10:1) served as a model of the phospholipid composition of the outer erythrocyte leaflet (37), and PE/PG vesicles (7:3) were used to mimic the phospholipid composition of E. coli (38). We found a direct correlation between the potential of the peptides to permeate model phospholipid membranes and their lytic activity against erythrocytes and E. coli. Only the hemolytic peptide [D]-L3,4,8,10-K3L9 permeated the zwitterionic phospholipid vesicles. Furthermore, the ability of the peptides to permeate PE/PG vesicles correlates with the antibacterial activity of the peptides against E. coli (Table II). [D]-L3,4,8,10-K7L5, which has the lowest antibacterial activity, also had significantly decreased ability to permeate PE/PG vesicles compared with the other three peptides.


Fig. 2. Maximal dissipation of the diffusion potential in vesicles, induced by the peptides. The peptides were added to isotonic K+ free buffer containing small unilamellar vesicles composed of PC (A) or PE/PG (B), pre-equilibrated with the fluorescent dye diS-C2-5 and valinomycin. Fluorescence recovery was measured 3-10 min after the peptides were mixed with the vesicles. Designations are as follows: black-square, [D]-L3,4,8,10-K3L9; bullet , [D]-L3,4,8,10-K4L8; black-triangle, [D]-L3,4,8,10-K5L7; oplus , [D]-L3,4,8,10-K7L5.
[View Larger Version of this Image (18K GIF file)]

Electron Microscopy Study of Bacterial Lysis

The effect of the diastereomers on the morphology of treated E. coli was visualized using transmission electron microscopy. All the peptides caused total lysis of the bacteria at the MIC (data not shown). However, when the peptides were utilized at concentrations corresponding to 80% of their MIC, some differences in the morphology of the treated bacteria were observed, depending upon the peptide used. The most hydrophobic peptide, [D]-L3,4,8,10-K3L9, caused the most damage to the cell wall and membranes, whereas the least hydrophobic peptide, [D]-L3,4,8,10-K7L5, only caused local perturbations (Fig. 3).


DISCUSSION

Previous studies with model peptides used to elucidate the structure-function study of antibacterial peptides focused on three parameters: helical structure, hydrophobicity, and charge (20-24). Each change in one of these parameters simultaneously resulted in changes in the other two, making it difficult to clarify the unique contribution of each parameter to the overall antibacterial activity. In this study, the effect of the helical structure was eliminated, which therefore permitted the study of only two parameters, namely, hydrophobicity and net positive charge, by varying the ratio of leucine and lysine. For this purpose, we chose to investigate diastereomers of short model peptides (12 amino acids long) containing stretches of only 1-3 consecutive L-amino acids, which are too short to form an alpha -helical structure.

CD spectroscopy revealed that the diastereomers studied here are indeed totally devoid of alpha -helical structure (data not shown), unlike the diastereomers of melittin and pardaxin, which retain low alpha -helical structure (25, 26). Nevertheless, the diastereomers exhibit potent antibacterial activity similar to or greater than that of native antibacterial peptides such as dermaseptin S or the antibiotic drug tetracycline (Table II). Moreover, the most potent peptides, [D]-L3,4,8,10-K4L8 and [D]-L3,4,8,10-K5L7, were devoid of hemolytic activity against the highly cytolytically susceptible human erythrocytes. It should be noted that [D]-L3,4,8,10-K3L9, which is devoid of alpha -helical structure, has considerable hemolytic activity that approaches that of the native cytolytic peptide, pardaxin (13). This could indicate that the balance between hydrophobicity and positive charge compensates for the amphipathic alpha -helical structure. However, increasing the positive charge drastically reduced the hemolytic activity while antibacterial activity was preserved, demonstrating that alpha -helical structure is not required for antibacterial activity.

The interaction of the diastereomers with both negatively charged and zwitterionic phospholipid membranes was examined to elucidate the basis of their selective cytotoxicity against bacteria. Negatively charged PE/PG vesicles were used to mimic the lipid composition of E. coli (38), and the zwitterionic PC vesicles to mimic the outer leaflet of human erythrocytes (37). The biological activity of the peptides on erythrocytes (Fig. 1) and E. coli (Table II) correlates well with their ability to permeate model membranes. The only peptide that permeated PC vesicles was the only peptide with significant hemolytic activity. These results suggest that the phospholipid composition of the bacterial membrane plays a role in permeation by this family of antibacterial peptides. The ability of antibacterial and nonhemolytic peptides to bind and permeate negatively charged but not zwitterionic phospholipid vesicles is characteristic of of native antibacterial peptides (15-17, 39) and has been attributed to the fact that the bacterial surface contains lipopolysaccharides (in Gram-negative bacteria) and polysaccharides (teichoic acids, in Gram-positive bacteria), and their inner membranes contain PG, all of which are negatively charged, whereas normal eukaryotic cells such as erythrocytes predominantly express the zwitterionic phospholipid PC on their outer leaflet.

The antibacterial peptide, magainin, is a nonhemolytic peptide, whereas melittin, pardaxin, and a model peptide with a sequence similar to that of [D]-L3,4,8,10-K4L8 but composed of entirely L-amino acids are hemolytic, mainly due to their high hydrophobicity. When the alpha -helical structure of magainin was disrupted by the introduction of three D-amino acids, the resulting diastereomer had no antibacterial activity (19), even though its net positive charge is similar to that of native magainin. Thus, an optimal balance that already exists between the alpha -helical structure, hydrophobicity, and net positive charge of native magainin allows selective antibacterial activity, and any change in one of these properties could cause a loss in magainin's antibacterial activity. Contrastingly, hydrophobicity appears to play a major role in compensating for the loss of alpha -helical structure in melittin, pardaxin, and the diastereomers studied in this paper.

Kiyota et al. recently examined how the hydrophobic-hydrophilic balance of apolar and polar surfaces of amphipathic positively charged helices affect membrane lytic activity (40). The results demonstrate that model peptides with a hydrophobic face larger than their hydrophilic face immerse their hydrophobic regions in lipid bilayers, whereas peptides with a hydrophilic positively charged face larger than hydrophobic face interact with the anionic lipid head groups on liposome surfaces. Thus, there appear to be two stages in the lytic process: binding and immersion into the hydrophobic core of the lipid bilayer, which then leads to membrane lysis. The concept of peptide hydrophobic-hydrophilic balance may also be applicable in the diastereomeric model peptides, even though they lack alpha -helicity. Electrostatic interactions between the positively charged diastereomers and the negatively charged phospholipid membranes seem to have an important role in initial interactions and selectivity, but biological activity appears to be driven by the hydrophobic interactions between the nonpolar amino acids and the hydrophobic core of the lipid bilayer. High hydrophobicity may force the immersion of the peptide into the hydrophobic core of the lipid bilayer, regardless of the phospholipid head group, thereby permeabilizing membranes of eukaryotic and prokaryotic cells, as found in the case of [D]-L3,4,8,10-K3L9. On the other hand high positive charge may prevent efficient immersion step, so that the peptide interacts predominantly with the negatively charged lipid head group as found in the case of [D]-L3,4,8,10-K7L5 (Table II). Within the constraints of high hydrophobicity and high positive charge, the peptide may acquire selective activity as a result of electrostatic interactions with lipid head groups and high antibacterial activity driven by hydrophobicity that immerses the peptide into the hydrophobic core of the lipid bilayer, resulting in lysis.

The results presented here, together with those obtained with diastereomers of pardaxin (25) and melittin (26), suggest a new strategy for the design of a repertoire of short, simple, and easily manipulated antibacterial peptides. Each of the diastereomeric model peptides has a unique spectrum of activity (Table II). The existence of a repertoire of diastereomeric antibacterial peptides will enable one to choose the most efficacious peptide with regard to the target cell. Furthermore, simultaneous administration of multiple forms of diastereomers peptides, acting separately or in concert, also has a selective survival value and provides a better shielding against a wider range of infectious microbes. All the peptides displayed increased antibacterial activity against Gram-positive in comparison to Gram-negative bacteria. These results are important considering the increasing resistance of Gram-positive bacteria such as Staphylococcus aureus, enterococci, and pneumococci to conventional antibiotics (1). In addition, unlike the native antibacterial peptide dermaseptin S, [D]-L3,4,8,10-K5L7 retained its antibacterial activity in the presence of pooled human serum.

Diastereomeric peptides should have several advantages over known antibacterial peptides: 1) The peptides should lack the diverse pathological and pharmacological effects induced by alpha -helical lytic cytolysins. For example, staphylococcus delta -toxin, the antibacterial peptide alamethicin, cobra direct lytic factor, and pardaxin exert several histopathological effects on various cells due to pore formation and activation of the arachidonic acid cascade. However, pardaxin diastereomers do not exert these activities (25). In addition, many amphipathic alpha -helical peptides bind to calmodulin and elicit several cell responses, and even all D-amino acid alpha -helices, including melittin have similar activity (41). Diastereomers with disrupted alpha -helical structure are not expected to bind to calmodulin. 2) Local D-amino acid substitution would result in controlled clearance of the antibacterial peptides by proteolytic enzymes, as opposed to the total protection acquired by complete D-amino acids substitution (42). Total resistance of a lytic peptide to degradation is disadvantageous for therapeutic use. Furthermore, the antigenicity of short fragments containing D,L-amino acids is dramatically altered as compared with their wholly L- or D-amino acid parent molecules (43). 3) Total inhibition of bacterial growth induced by the diastereomers is associated with total lysis of the bacterial wall, as shown by electron microscopy (Fig. 3). Therefore, bacteria might not easily develop resistance to drugs that trigger such a destructive mechanism. 4) [D]-L3,4,8,10-K5L7 has the ability to perturb the cell wall of bacteria at concentrations lower than their MIC, as seen by electron microscopy (Fig. 3). The simultaneous administration of clinically used antibiotics, which have no activity due to their inability to penetrate the bacterial cell wall, together with [D]-L3,4,8,10-K5L7 may present a solution to this resistance mechanism of bacteria.

In summary, the results obtained with pardaxin, melittin, and the model peptide diastereomers indicate that neither a specific sequence, length, or position of D-amino acids are required for a polypeptide to have antibacterial activity. However, these factors seem to be more crucial for cytotoxicity toward mammalian cells. Our results indicate that only modulating the hydrophobicity and net positive charge of linear cytotoxic polypeptides is sufficient in the design of a repertoire of potent antibacterial diastereomeric polypeptides for the treatment of infectious diseases.


FOOTNOTES

*   This research was supported by the Israel Academy of Sciences and Humanities and by the Pasteur-Weizmann Research Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    To whom correspondence should be addressed. Tel.: 972-8-9342711; Fax: 972-8-9344112; E-mail: bmshai{at}weizmann.weizmann.ac.il.
1   The abbreviations used are: PC, egg phosphatidylcholine; diS-C2-5, 3,3'-diethylthiodicarbocyanine iodode; hRBC, human red blood cells; MIC, minimal inhibitory concentration; PBS, phosphate-buffered saline; PE, phosphatidylethanolamine; PG, egg phosphatidylglycerol; HPLC, high performance liquid chromatography.

REFERENCES

  1. Russell, P. E., Milling, R. J., and Wright, K. (1995) in Fifty Years of Antimicrobials: Past Perspectives and Future Trends (Hunter, P. A., Darby, G. K., and Russell, N. J., eds), pp. 67-85, Cambridge University Press, Cambridge
  2. Steiner, H., Hultmark, D., Engstrom, A., Bennich, H., and Boman, H. G. (1981) Nature 292, 246-248 [Medline] [Order article via Infotrieve]
  3. Zasloff, M. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 5449-5453 [Abstract]
  4. Agerberth, B., Gunne, H., Odeberg, J., Kogner, P., Boman, H. G., and Gudmundsson, G. H. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 195-199 [Abstract]
  5. Saberwal, G., and Nagaraj, R. (1994) Biochim. Biophys. Acta 1197, 109-131 [Medline] [Order article via Infotrieve]
  6. Boman, H. G. (1995) Annu. Rev. Immunol. 13, 61-92 [CrossRef][Medline] [Order article via Infotrieve]
  7. Nicolas, P., and Mor, A. (1995) Annu. Rev. Microbiol. 49, 277-304 [CrossRef][Medline] [Order article via Infotrieve]
  8. Segrest, J. P., DeLoof, H., Dohlman, J. G., Brouillette, C. G., and Anantharamaiah, G. M. (1990) Proteins 8, 103-117 [Medline] [Order article via Infotrieve]
  9. Habermann, E., and Jentsch, J. (1967) Hoppe Seyler's Z. Physiol. Chem. 348, 37-50 [Medline] [Order article via Infotrieve]
  10. Lazarovici, P., Primor, N., and Loew, L. M. (1986) J. Biol. Chem. 261, 16704-16713 [Abstract/Free Full Text]
  11. Shai, Y., Fox, J., Caratsch, C., Shih, Y. L., Edwards, C., and Lazarovici, P. (1988) FEBS Lett. 242, 161-166 [CrossRef][Medline] [Order article via Infotrieve]
  12. Boman, H. G., Wade, D., Boman, I. A., Wahlin, B., and Merrifield, R. B. (1989) FEBS Lett. 259, 103-106 [CrossRef][Medline] [Order article via Infotrieve]
  13. Oren, Z., and Shai, Y. (1996) Eur. J. Biochem. 237, 303-310 [Abstract]
  14. Mor, A., Nguyen, V. H., Delfour, A., Migliore, S. D., and Nicolas, P. (1991) Biochemistry 30, 8824-8830 [Medline] [Order article via Infotrieve]
  15. Pouny, Y., Rapaport, D., Mor, A., Nicolas, P., and Shai, Y. (1992) Biochemistry 31, 12416-12423 [Medline] [Order article via Infotrieve]
  16. Gazit, E., Lee, W. J., Brey, P. T., and Shai, Y. (1994) Biochemistry 33, 10681-10692 [Medline] [Order article via Infotrieve]
  17. Strahilevitz, J., Mor, A., Nicolas, P., and Shai, Y. (1994) Biochemistry 33, 10951-10960 [Medline] [Order article via Infotrieve]
  18. Andreu, D., Merrifield, R. B., Steiner, H., and Boman, H. G. (1985) Biochemistry 24, 1683-1688 [Medline] [Order article via Infotrieve]
  19. Chen, H. C., Brown, J. H., Morell, J. L., and Huang, C. M. (1988) FEBS Lett. 236, 462-466 [CrossRef][Medline] [Order article via Infotrieve]
  20. Anzai, K., Hamasuna, M., Kadono, H., Lee, S., Aoyagi, H., and Kirino, Y. (1991) Biochim. Biophys. Acta 1064, 256-266 [Medline] [Order article via Infotrieve]
  21. Agawa, Y., Lee, S., Ono, S., Aoyagi, H., Ohno, M., Taniguchi, T., Anzai, K., and Kirino, Y. (1991) J. Biol. Chem. 266, 20218-20222 [Abstract/Free Full Text]
  22. Cornut, I., Buttner, K., Dasseux, J. L., and Dufourcq, J. (1994) FEBS Lett. 349, 29-33 [CrossRef][Medline] [Order article via Infotrieve]
  23. Lee, S., Mihara, H., Aoyagi, H., Kato, T., Izumiya, N., and Yamasaki, N. (1986) Biochim. Biophys. Acta 862, 211-219 [Medline] [Order article via Infotrieve]
  24. Blondelle, S. E., and Houghten, R. A. (1992) Biochemistry 31, 12688-12694 [Medline] [Order article via Infotrieve]
  25. Shai, Y., and Oren, Z. (1996) J. Biol. Chem. 271, 7305-7308 [Abstract/Free Full Text]
  26. Oren, Z., and Shai, Y. (1997) Biochemistry 36, 1826-1835 [CrossRef][Medline] [Order article via Infotrieve]
  27. Merrifield, R. B., Vizioli, L. D., and Boman, H. G. (1982) Biochemistry 21, 5020-5031 [Medline] [Order article via Infotrieve]
  28. Bartlett, G. R. (1959) J. Biol. Chem. 234, 466-468 [Free Full Text]
  29. Papahadjopoulos, D., and Miller, N. (1967) Biochim. Biophys. Acta 135, 624-638 [Medline] [Order article via Infotrieve]
  30. Wu, C. S., Ikeda, K., and Yang, J. T. (1981) Biochemistry 20, 566-570 [Medline] [Order article via Infotrieve]
  31. Greenfield, N., and Fasman, G. D. (1969) Biochemistry 8, 4108-4116 [Medline] [Order article via Infotrieve]
  32. Loew, L. M., Rosenberg, I., Bridge, M., and Gitler, C. (1983) Biochemistry 22, 837-844 [Medline] [Order article via Infotrieve]
  33. Sims, P. J., Waggoner, A. S., Wang, C. H., and Hoffmann, J. R. (1974) Biochemistry 13, 3315-3330 [Medline] [Order article via Infotrieve]
  34. Shai, Y., Bach, D., and Yanovsky, A. (1990) J. Biol. Chem. 265, 20202-20209 [Abstract/Free Full Text]
  35. Shai, Y., Hadari, Y. R., and Finkels, A. (1991) J. Biol. Chem. 266, 22346-22354 [Abstract/Free Full Text]
  36. Eisenberg, D., Schwarz, E., Komaromy, M., and Wall, R. (1984) J. Mol. Biol. 179, 125-142 [Medline] [Order article via Infotrieve]
  37. Verkleij, A. J., Zwaal, R. F., Roelofsen, B., Comfurius, P., Kastelijn, D., and Van-Deenen, L. L. M. (1973) Biochim. Biophys. Acta 323, 178-193 [Medline] [Order article via Infotrieve]
  38. Shaw, N. (1974) Adv. Appl. Microbiol. 17, 63-108 [Medline] [Order article via Infotrieve]
  39. Mchaourab, H. S., Hyde, J. S., and Feix, J. B. (1994) Biochemistry 33, 6691-6699 [Medline] [Order article via Infotrieve]
  40. Kiyota, T., Lee, S., and Sugihara, G. (1996) Biochemistry 35, 13196-13204 [CrossRef][Medline] [Order article via Infotrieve]
  41. Fisher, P. J., Prendergast, F. G., Ehrhardt, M. R., Urbauer, J. L., Wand, A. J., Sedarous, S. S., McCormick, D. J., and Buckley, P. J. (1994) Nature 368, 651-653 [Medline] [Order article via Infotrieve]
  42. Wade, D., Boman, A., Wahlin, B., Drain, C. M., Andreu, D., Boman, H. G., and Merrifield, R. B. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 4761-4765 [Abstract]
  43. Benkirane, N., Friede, M., Guichard, G., Briand, J.-P., Van Regenmortel, R. M., and Muller, S. (1993) J. Biol. Chem. 268, 26279-26285 [Abstract/Free Full Text]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.